Funding for this research was provided by:
Alzheimer’s Research UK (ARUK-PG2017-1946, ARUK-PG2014-1946)
Medical Research Foundation (CSUB199166, MC_UU_12019/1, MC_UU_12019/2, MC_UU_12019/3)
Wolfson Foundation (PR/y1r/18575)
Received: 2 December 2020
Accepted: 12 April 2021
First Online: 30 April 2021
: Ethical approvals for the wider NSHD have been described [CitationRef removed]. Insight 46 was approved by the Queen Square Research Ethics Committee. All participants provided written informed consent.
: All participants provided written informed consent for publication.
: Christopher A. Lane –Subsequent to preparation of manuscript is now a full-time employee of Hoffmann-La Roche UK Ltd.Josephine Barnes – Was supported by an Alzheimer’s Research UK senior fellowship.Jennifer M. Nicholas – Reports no disclosures.John W. Baker – Reports no disclosures.Carole H. Sudre – Supported by an Alzheimer’s Society Junior Fellowship (AS-JF-17-011).David M. Cash – Reports no disclosures.Thomas D. Parker - Supported by a Wellcome Trust Clinical Research Fellowship (200109/Z/15/Z).Ian B. Malone – Reports no disclosures.Kirsty Lu – Reports no disclosures.Sarah-Naomi James – Reports no disclosures.Ashvini Keshavan – Reports no disclosures.Sarah Buchanan – Reports no disclosures.Sarah Keuss – Reports no disclosures.Heidi Murray-Smith – Reports no disclosures.Andrew Wong – Reports no disclosures.Elizabeth Gordon – Reports no disclosures.William Coath – Reports no disclosures.Marc Modat – Reports no disclosure.David Thomas – Reports no disclosures.Rebecca Hardy – Reports no disclosures.Marcus Richards – Reports no disclosures.Nick C. Fox – NCF’s research group has received payment for consultancy or for conducting studies from Biogen, Eli Lilly Research Laboratories, GE Healthcare, and Roche. NCF receives no personal compensation for the activities mentioned above. He is supported by the UCL/UCLH NIHR Biomedical Research Centre, Leonard Wolfson Experimental Neurology Centre, UK Dementia Research Institute at UCL, an NIHR Senior Investigator award, and additional funding from the NIA and EPSRC.Jonathan M. Schott - JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, Merck and Eli Lilly, given educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. He is supported by the UCL/UCLH NIHR Biomedical Research Centre, UCL Hospitals Biomedical Research Centre, and Leonard Wolfson Experimental Neurology Centre. He acknowledges the EPSRC (EP/J020990/1), Weston Brain Institute (UB170045) and European Union’s Horizon 2020 research and innovation programme (Grant 666992).